Bezafibrate to prevent relapsing pancreatitis in WAGR syndrome.

Abstract

Recurrent episodes of acute, severe pancreatitis are a feature of the rare WAGR congenital anomaly syndrome. Although pancreatitis is well recognised as a life-threatening association of WAGR syndrome, treatment to prevent pancreatitis is not recommended. We report the successful prevention of hypertriglyceridaemia-associated relapsing pancreatitis in a child with WAGR syndrome with Bezafibrate. In addition to dietary fat restriction, Bezafibrate may be a useful therapeutic adjunct in WAGR related relapsing pancreatitis.

• Authors: Daniela Diacono, Andrew Fagbemi, Joanne Puleston, Indraneel Banerjee
• Journal: BMJ case reports (BMJ Case Rep) Vol. 2012 (Nov 14 2012) ISSN: 1757-790X [Electronic] England
• PMID: 23152176 (Publication Type: Case Reports, Journal Article)

Chemical References

• Hypolipidemic Agents
• Bezafibrate

Topics

• Bezafibrate (therapeutic use)
• Child
• Combined Modality Therapy
• Diet, Fat-Restricted
• Female
• Humans
• Hypertriglyceridemia (complications, drug therapy)
• Hypolipidemic Agents (therapeutic use)
• Pancreatitis, Acute Necrotizing (prevention & control)
• Prognosis
• Secondary Prevention
• WAGR Syndrome (complications)